Online inquiry

IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9252MR)

This product GTTS-WQ9252MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CEACAM5 gene. The antibody can be applied in Colorectal Cancer (CRC) Cancers (CRC) Cancers (CRC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001291484.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1048
UniProt ID P06731
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9252MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14740MR IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA SGN-19A
GTTS-WQ6615MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ8937MR IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IL-1 Trap
GTTS-WQ15195MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA TA-650
GTTS-WQ7311MR IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FPA-144
GTTS-WQ1524MR IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACE-031
GTTS-WQ704MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA A-1230717
GTTS-WQ596MR IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA 6A3-IgG4
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW